The Maudsley Prescribing Guidelines in Psychiatry (eBook)

David M. Taylor, Thomas R. E. Barnes, Allan H. Young (Autoren)

eBook Download: EPUB

2021 | 14. Auflage
John Wiley & Sons (Verlag)
978-1-119-77223-1 (ISBN)

Infos

The Maudsley^® Prescribing Guidelines in Psychiatry

The new edition of the world-renowned reference guide on the use of medications for patients presenting with mental health problems

The Maudsley Prescribing Guidelines in Psychiatry is the essential evidence-based handbook on the safe and effective prescribing of psychotropic agents. Covering both common and complex prescribing situations encountered in day-to-day clinical practice, this comprehensive resource provides expert guidance on drug choice, minimum and maximum doses, adverse effects, switching medications, prescribing for special patient groups, and more. Each clear and concise chapter includes an up-to-date reference list providing easy access to the evidence on which the guidance is based.

The fourteenth edition has been fully updated to incorporate the latest available research, the most recent psychotropic drug introductions, and all psychotropic drugs currently used in the UK, USA, Canada, Australia, New Zealand, and Japan. Several new sections cover topics such as deprescribing of major psychiatric drugs, prescribing psychotropics at the end of life, the treatment of agitated delirium, the genetics of clozapine prescribing, the use of weekly penfluridol, and the treatment of psychotropic withdrawal. Featuring contributions by an experienced team of psychiatrists and specialist pharmacists, the new edition of The Maudsley Prescribing Guidelines in Psychiatry:

• Provides succinct coverage of drug treatment of psychiatric conditions and formulating prescribing policy in mental health
• Covers a wide range of psychiatric conditions including schizophrenia, bipolar disorder, depression and anxiety, borderline personality, eating disorders, and many others
• Provides advice on prescribing for children and adolescents, older people, pregnant women, and other special patient groups
• Offers new sections on genetic prescribing, long-acting injectable formulations, ketamine administration and uses, and dopamine super-sensitivity
• Includes referenced information on off-label prescribing, potential interactions with other substances such as alcohol, tobacco, and caffeine, and treating patients with comorbid physical conditions

Whether in the doctor's office, in the clinic, or on the ward, The Maudsley Prescribing Guidelines in Psychiatry, Fourteenth Edition is a must-have for psychiatrists, pharmacists, neuropharmacologists, clinical psychologists, nurses, and other healthcare professionals working in mental health, as well as trainees and students in medicine, pharmacy, and nursing.

David M. Taylor, BSc, MSc, PhD, FFRPS, FRPharmS, FRCPsych (Hon) is Director of Pharmacy and Pathology at the Maudsley Hospital and Professor of Psychopharmacology at King's College, London.

Thomas R. E. Barnes, MBBS, MD, FRCPsych, DSc, is Emeritus Professor of Clinical Psychiatry at Imperial College London and joint-head of the Prescribing Observatory for Mental Health at the Royal College of Psychiatrists' Centre for Quality Improvement.

Allan H. Young, MB, ChB, MPhil, PhD, FRCPC, FRCPsych, is Chair of Mood Disorders and is Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry at King's College London, UK.

Inhalt

Preface xi

Acknowledgments xii

Notes on using The Maudsley Prescribing Guidelines in Psychiatry xiii

List of abbreviations xv

Part 1 Drug treatment of major psychiatric conditions 1

Chapter 1 Schizophrenia and related psychoses 3

ANTIPSYCHOTIC DRUGS 3

ANTIPSYCHOTIC ADVERSE EFFECTS 109

REFRACTORY SCHIZOPHRENIA AND CLOZAPINE 190

CLOZAPINE ADVERSE EFFECTS 212

Chapter 2 Bipolar disorder 247

Chapter 3 Depression and anxiety disorders 305

Chapter 4 Addictions and substance misuse 451

Part 2 Drug treatment of special patient groups 537

Chapter 5 Children and adolescents 539

Chapter 6 Prescribing in older people 601

Chapter 7 Pregnancy and breastfeeding 679

Chapter 8 Hepatic and renal impairment 723

Part 3 Prescribing in specialist conditions 755

Chapter 9 Drug treatment of other psychiatric conditions 757

Chapter 10 Drug treatment of psychiatric symptoms occurring in the context of other disorders 777

Part 4 Other aspects of psychotropic drug use 831

Chapter 11 Pharmacokinetics 833

Chapter 12 Other substances 865

Chapter 13 Psychotropic drugs in special conditions 875

Chapter 14 Miscellany 897

Index 943

Textauszug

List of abbreviations

AACAP

American Academy of Child and Adolescent Psychiatry

ACE	angiotensin‐converting enzyme

ACh	acetylcholine

AChE	acetylcholinesterase

AChE‐I

acetylcholinesterase inhibitor

ACR	albumin: creatinine ratio

AD	Alzheimer’s disease

ADAS‐cog

Alzheimer’s Disease Assessment Scale – cognitive subscale

ADH	alcohol dehydrogenase

ADHD	attention deficit hyperactivity disorder

ADIS	Anxiety Disorders Interview Schedule

ADL	activities of daily living

ADR	adverse drug reaction

AF	atrial fibrillation

AIDS	acquired immune deficiency syndrome

AIMS	Abnormal Involuntary Movement Scale

ALP	alkaline phosphatase

ALT	alanine transaminase/aminotransferase

ANC	absolute neutrophil count

ANNSERS

Antipsychotic Non‐Neurological Side‐Effects Rating Scale

APA	American Psychological Association

ARB	angiotensin II receptor blocker

ASD	autism spectrum disorders

ASEX	Arizona Sexual Experience Scale

AST	aspartate aminotransferase

AUDIT

Alcohol Use Disorders Identification Test

BAC	blood alcohol concentration

BAP	British Association for Psychopharmacology

BBB	blood–brain barrier

bd	bis die (twice a day)

BDD	body dysmorphic disorder

BDI	Beck Depression Inventory

BDNF	brain‐derived neurotrophic factor

BED	binge eating disorder

BEN	benign ethnic neutropenia

BMI	body mass index

BN	bulimia nervosa

BP	blood pressure

BPD	borderline personality disorder

BPSD	behavioural and psychological symptoms of dementia

BuChE

butyrylcholinesterase

CAM	Confusion Assessment Method

CAMS	Childhood Anxiety Multimodal Study

CATIE

Clinical Antipsychotic Trials of Intervention Effectiveness

CBT	cognitive behavioural therapy

CBZ	carbamazepine

CDRS	Children’s Depression Rating Scale

CDT	carbohydrate‐deficient transferrin

CES‐D

Centre for Epidemiological Studies Depression scale

CGAS	Children’s Global Assessment Scale

CGI	Clinical Global Impression scales

CI	confidence interval

CIBIC‐Plus

Clinician’s Interview‐Based Impression of Change

CIGH	clozapine‐induced gastrointestinal hypomotility

CIWA‐Ar

Clinical Institute Withdrawal Assessment of Alcohol scale revised

CK	creatine kinase

CKD	chronic kidney disease

CKD‐EPI

Chronic Kidney Disease Epidemiology Collaboration

CNS	central nervous system

COMT	catechol‐O‐methyltransferase

COPD	chronic obstructive pulmonary disease

COX	cyclo‐oxygenase

CPK	creatinine phosphokinase

CPP	child–parent psychotherapy

CPSS	Child PTSD Symptom Scale

CrCl	creatinine clearance

CREB	cAMP response element‐binding protein

CRP	C‐reactive protein

CUtLASS

Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study

CVA	cerebrovascular accident

CY‐BOCS

Children’s Yale‐Brown Obsessive Compulsive Scale

CYP	cytochrome P

DAI	drug attitude inventory

DESS	Discontinuation–Emergent Signs and Symptoms scale

DEXA	dual‐energy X‐ray absorptiometry

DHEA	dehydroepiandrosterone

DIVA	Diagnostic Interview for DSM‐IV ADHD

DLB	dementia with Lewy bodies

DMDD	disruptive mood dysregulation disorder

DOAC	direct‐acting oral anticoagulant

DoLS	Deprivation of Liberty Safeguards

DSM	Diagnostic and Statistical Manual of Mental Disorders

DVLA	Driver and Vehicle Licensing Agency

EAD	early after depolarisation

ECG	electrocardiogram

ECT	electroconvulsive therapy

EDTA	ethylenediaminetetraacetic acid

EEG	electroencephalogram

eGFR	estimated glomerular filtration rate

EMDR	eye movement desensitisation and reprocessing

EOSS	early‐onset schizophrenia‐spectrum

EPA	eicosapentanoic acid

EPS	extrapyramidal symptoms

ER	extended release

ERK	extracellular signal‐regulated kinase

ERP	exposure and response prevention

ES	effect size

ESR	erythrocyte sedimentation rate

FAST	functional assessment staging

FBC	full blood count

FDA	Food and Drug Administration (USA)

FGA	first‐generation antipsychotic

FPG	fasting plasma glucose

FTI	Fatal Toxicity Index

GABA	γ‐aminobutyric acid

GAD	generalised anxiety disorder

GASS	Glasgow Antipsychotic Side‐effect Scale

GBL	gamma-butyrolactone

G‐CSF

granulocyte colony‐stimulating factor

GFR	glomerular filtration rate

GGT	γ‐glutamyl transferase

GHB	γ‐hydroxybutyrate

GI	gastrointestinal

GM‐CSF

granulocyte‐macrophage colony-stimulating factor

GSK3	glycogen synthase kinase 3

HADS	Hospital Anxiety and Depression Scale

HAMA	Hamilton Anxiety Rating Scale

HAND	HIV‐associated neurocognitive disorders

HD	Huntington’s disease

HDL	high‐density lipoprotein

HDRS	Hamilton Depression Rating...

Produkt-Details

• Erscheint lt. Verlag: 13.7.2021
• Reihe/Serie: The Maudsley Prescribing Guidelines Series
• Reihe/Serie: The Maudsley Prescribing Guidelines Series
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Gesundheitsfachberufe
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie
• Schlagworte: Clinical psychology • Klinische Psychologie • Medical Science • Medizin • Pharmacy • Pharmazie • psychiatric drug treatment • psychiatric prescribing guide • Psychiatrie • Psychiatry • psychiatry prescribing • psychiatry prescribing handbook • psychiatry prescribing reference • Psychologie • Psychology • psychotropic drug adverse effects • psychotropic drug interactions • psychotropic prescribing
• ISBN-10: 1-119-77223-0 / 1119772230
• ISBN-13: 978-1-119-77223-1 / 9781119772231